Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/09/05 18:22:54」(JST)

Aranidipine (INN, trade name Sapresta) is a calcium channel blocker.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

English Journal

[Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension].

Jiao Y1, Chen L, Zheng JT, Ke YN2, Wang Y, Yang HY, Jin H, Zhao XL, Liu MX, Wang L, Wang BY, Li DY.
Zhonghua yi xue za zhi.Zhonghua Yi Xue Za Zhi.2013 Oct 22;93(39):3104-10.
OBJECTIVE: To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension.METHODS: This was a multicenter, randomized, double-blind, placebo and active antihypertensive drug parallel-controlled study. After 2 weeks
PMID 24417987

[The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension].

Chen L1, Jiang H, Hua Q, Yang HY, Zheng JT, Jin H, Jiao Y, Wang Y, Sun RH, Ke YN.
Zhonghua nei ke za zhi.Zhonghua Nei Ke Za Zhi.2013 Sep;52(9):749-52.
OBJECTIVE: To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension.METHODS: This was an open clinical trial with 2 weeks of placebo run-in period. A total of 74 patients with bl
PMID 24314165

Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial.

Yan LR1, Li YS, Chen GL, Wang L, Pang HM, Wu SY, Yu J, Li HM, Lin YZ, Zhao RP, Fan CM.
Journal of cardiovascular pharmacology.J Cardiovasc Pharmacol.2012 Jul;60(1):8-14. doi: 10.1097/FJC.0b013e318254a566.
This is a multicenter, randomized, double-blind, parallel-controlled study, conducted in Chinese patients with mild to moderate essential hypertension. After a 2-week washout period, 236 eligible patients were randomly to receive aranidipine 5-10 mg/d (n = 118) or amlodipine 5-10 mg/d (n = 118) for
PMID 22441301

Inhibition of T-type and L-type Ca^<2+> currents by aranidipine, a novel dihydropyridine Ca^<2+> antagonist

Distinct action of aranidipine and its metabolite on renal microvessels with special reference to renal protection

Aranidipine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name O5-methyl O3-(2-oxopropyl);
CAS Number	86780-90-7 ;
PubChem CID	2225;
ChemSpider	2139 ;
UNII	4Y7UR6X2PO;
KEGG	D01562 ;
ChEMBL	CHEMBL2104030;
Chemical and physical data
Formula	C19H20N2O7
Molar mass	388.37 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC ;
	InChI InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3 ; Key:NCUCGYYHUFIYNU-UHFFFAOYSA-N ;
(verify)

Clinical data


AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name O5-methyl O3-(2-oxopropyl)
CAS Number	86780-90-7^Y
PubChem CID	2225
ChemSpider	2139^Y
UNII	4Y7UR6X2PO
KEGG	D01562^Y
ChEMBL	CHEMBL2104030
Chemical and physical data
Formula	C₁₉H₂₀N₂O₇
Molar mass	388.37 g/mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
InChI InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3^Y Key:NCUCGYYHUFIYNU-UHFFFAOYSA-N^Y
(verify)